Mechanisms underlying the blood pressure-lowering effects of empagliflozin, losartan and their combination in people with type 2 diabetes: A secondary analysis of a randomized crossover trial
Diabetes Obes Metab. 2022; online ahead of print DOI: 10.1111/dom.14864
In this crossover study involving participants with T2D, empagliflozin in combination with losartan had a larger blood pressure-lowering effect than either of the drugs alone when compared with placebo. Empagliflozin reduced arterial stiffness, sympathetic nervous system (SNS) activity and extracellular fluid, while also increasing serum albumin. Losartan only reduced SNS activity and arterial stiffness. The authors concluded the mechanisms underlying blood-pressure reductions may at least partially differ between the two agents.